Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 90. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects764
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma437
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer433
Targeting GPRC5D for multiple myeloma therapy430
Involvement of inflammasomes in tumor microenvironment and tumor therapies424
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML400
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans385
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer333
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer328
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management327
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial320
Helicobacter pylori and gastric cancer: mechanisms and new perspectives311
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting290
Cancer vaccines: current status and future directions288
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL271
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders263
Gene and cell therapies in China: booming landscape under dual-track regulation260
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies255
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma251
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ244
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents244
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1230
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA226
A four-stage model for murine natural killer cell development in vivo225
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report225
Current and future treatment strategies in chronic lymphocytic leukemia219
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT208
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden203
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena202
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma197
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and195
Emerging role of RNA sensors in tumor microenvironment and immunotherapy180
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening177
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial176
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation174
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China173
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer167
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia164
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation153
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting152
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients149
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency148
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast146
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024146
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy146
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients144
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells142
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018141
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium131
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)126
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint125
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC124
Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting124
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer124
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype119
Correction: A single-cell and spatially resolved atlas of human osteosarcomas119
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study118
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential116
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy115
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma113
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine112
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine111
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin111
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial108
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence108
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia107
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials106
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors106
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma104
Recent developments in immunotherapy for gastrointestinal tract cancers103
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy102
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation101
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML99
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells99
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies98
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses98
Mesenchymal stem/stromal cells in cancer therapy98
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leuke98
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients97
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis97
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation96
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives96
Integrins regulate stemness in solid tumor: an emerging therapeutic target96
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms96
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation95
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma95
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies93
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy93
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer92
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing90
2.501660823822